Abstract
Background Smoking is a well-established risk factor for abdominal aortic aneurysm (AAA). However, the molecular pathways underlying this relationship remain poorly understood. This study aimed to identify circulating protein mediators that may explain the association between smoking and AAA.
Methods We conducted a network Mendelian randomization (MR) study utilizing summary-level data from the largest available genome-wide association studies. Our primary smoking exposure was the lifetime smoking index, with smoking initiation and cigarettes per day included as supplementary traits. The AAA dataset comprised 39,221 cases and 1,086,107 controls. Protein data were sourced from two large cohorts: UKB-PPP, where proteins were measured using the Olink platform in 54,219 individuals, and deCODE, where proteins were measured using the SomaScan platform in 35,559 individuals. Two-sample MR was employed to estimate the association between smoking and AAA (βtotal) and between smoking and circulating protein levels (β1). Summary data-based MR was then used to assess the association between smoking-related proteins and AAA risk (β2). Mediation pathways were identified based on the directionality of effect estimates, and the corresponding mediation effects were quantified.
Results Genetically predicted smoking traits were consistently associated with an increased risk of AAA. The lifetime smoking index was associated with the levels of 543 out of 5,764 unique circulating proteins, with 470 of these associations replicated in supplementary analyses using additional smoking traits and protein sources. Among the smoking-related proteins, genetically predicted levels of 22 were associated with AAA risk. Eight mediation pathways were identified accounting for 42.7% of the total smoking-AAA association and with mediation effects >4% for ADAMTS15, IL1RN, MMP12, PGF, PCSK9, and UXS1.
Conclusion This study identified numerous circulating proteins potentially causally linked to smoking, and eight of these proteins were found to mediate the association between smoking and AAA risk.
Competing Interest Statement
S.M.D. receives research support from RenalytixAI and in-kind research support from Novo Nordisk and Amgen, both outside the scope of the current project. Other authors declare no conflict of interests.
Funding Statement
S.Y. is supported by the American Heart Association Postdoctoral Fellowship (https://doi.org/10.58275/AHA.24POST1189614.pc.gr.190880). This work was supported by NIH R01-HL166991 to S.M.D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
protein data from deCODE (https://www.decode.com/summarydata/), UKB-PPP (http://ukb-ppp.gwas.eu/), Fenland (http://www.omicscience.org/apps/pgwas) GWAS results. AAA data from AAAgen GWAS results (https://csg.sph.umich.edu/willer/public/AAAgen2023/). Smoking data from GWAS of smoking initiation (https://conservancy.umn.edu/items/91f6a003-6af2-4809-9785-53dc579dc788), cigarettes smoked per day (https://conservancy.umn.edu/items/91f6a003-6af2-4809-9785-53dc579dc788), and lifetime smoking index (https://data.bris.ac.uk/data/dataset/10i96zb8gm0j81yz0q6ztei23d).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
